{"id":"W3042132061","doi":"10.1016/s1470-2045(20)30326-0","title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; McMaster University; Juravinski Cancer Centre","funders":"Merck Sharp and Dohme; MacroGenics","keywords":"Pembrolizumab; Gastro-; Medicine; Internal medicine; Adenocarcinoma; Gastroenterology; Oncology; Cancer; Immunotherapy; Reflux; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006523718,0.0004094721,0.001489822,0.0001474666,0.0001200792,0.00004183314,0.0005511676,0.0002588271,0.0004346384],"category_scores_gemma":[0.0003227616,0.0002764652,0.0001373324,0.0006356877,0.0004243752,0.0001051118,0.0002087242,0.001223194,0.0001366548],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001642761,"about_ca_system_score_gemma":0.001090023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003152516,"about_ca_topic_score_gemma":0.0001745089,"domain_scores_codex":[0.9956459,0.001005776,0.000615057,0.0007450034,0.0007401691,0.001248136],"domain_scores_gemma":[0.9980675,0.0003759349,0.0002408109,0.0006503909,0.0002178633,0.0004475172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8475304,0.01106489,0.09510067,0.0003481978,0.000413252,0.003419372,0.006298616,0.00003168079,0.0002798356,0.00009564063,0.01550853,0.01990898],"study_design_scores_gemma":[0.7851749,0.1384007,0.0605008,0.0002699918,0.0003869879,0.0002122769,0.0003790832,0.000628896,0.0007039662,0.00004666529,0.01284211,0.0004535769],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769991,0.0005365351,0.00006382979,0.01214346,0.0002164592,0.004178016,0.0001294657,0.0001328184,0.005600318],"genre_scores_gemma":[0.9930853,0.00005196775,0.0004725218,0.003780975,0.001715218,0.0003978895,0.0001762984,0.00009237432,0.0002274462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1273359,"threshold_uncertainty_score":0.9999688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07346060626970793,"score_gpt":0.3594422757535952,"score_spread":0.2859816694838873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}